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Abstract
Summary FRAX-based cost-effective intervention thresholds
in the Swiss setting were determined. Assuming a willingness
to pay at 2× Gross Domestic Product per capita, an interven-
tion aimed at reducing fracture risk in women and men with a
10-year probability for a major osteoporotic fracture at or
above 15% is cost-effective.
Introduction The fracture risk assessment algorithm FRAX®
has been recently calibrated for Switzerland. The aim of the
present analysis was to determine FRAX-based fracture prob-
abilities at which intervention becomes cost-effective.
Methods Apreviously developed and validated state transition
Markov cohort model was populated with Swiss epidemiolog-
ical and cost input parameters. Cost-effective FRAX-based
intervention thresholds (cost-effectiveness approach) and the
cost-effectiveness of intervention with alendronate (original
molecule) in subjects with a FRAX-based fracture risk equiv-
alent to that of a woman with a prior fragility fracture and no
other risk factor (translational approach) were calculated based
on the Swiss FRAX model and assuming a willingness to pay
of 2 times Gross Domestic Product per capita for one Quality-
adjusted Life-Year.
Results In Swiss women and men aged 50 years and older,
drug intervention aimed at decreasing fracture risk was cost-
effective with a 10-year probability for a major osteoporotic
fracture at or above 13.8% (range 10.8% to 15.0%) and 15.1%
(range 9.9% to 19.9%), respectively. Age-dependent varia-
tions around these mean values were modest. Using the trans-
lational approach, treatment was cost-effective or cost-saving
after the age 60 years in women and 55 in men who had
previously sustained a fragility fracture. Using the latter ap-
proach leads to considerable underuse of the current potential
for cost-effective interventions against fractures.
Conclusions Using a FRAX-based intervention threshold of
15% for both women and men should permit cost-effective
access to therapy to patients at high fracture probability
based on clinical risk factors and thereby contribute to
further reduce the growing burden of osteoporotic fractures
in Switzerland.
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Introduction
Osteoporosis and its complications impose a high economic
burden on industrialized countries [1, 2]. At the age of
50 years, the remaining lifetime probability of sustaining a
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major osteoporotic fracture (clinical fracture of the hip,
spine, distal radius, and proximal humerus) in Switzerland is
51.3% and 20.2% in women and men, respectively [3]. Thus,
Switzerland is amongst the countries at highest risk for oste-
oporotic fractures [3]. In addition, Switzerland ranks second
worldwide with regard to the proportion of elderly in its
population [4], and the number of persons older than 65 years
is expected to double between the years 2005 and 2050 [5]. As
a result, health economic projections have shown that in the
absence of targeted interventions, the economic burden of
osteoporotic fractures to the Swiss healthcare system will
considerably increase in coming decades [6].
Bone mineral density (BMD) measured by dual X-ray
absorptiometry (DXA) is the current reference standard for
the diagnosis of osteoporosis. A femoral neck BMD at or
below 2.5 standard deviations (SD) the average mean value
of young healthy women (T-score≤−2.5 SD) was proposed
by the World Health Organization (WHO) as an operational
definition of osteoporosis [7–9]. The WHO also defined T-
scores between −1.0 and −2.49 SD as osteopenia [7–9]. As
fracture risk continuously increases with decreasing BMD,
these definitions were initially established to define normal
ranges and for epidemiologic purposes, and not intended as
thresholds for prescribing drugs [7]. However, since BMD is
one of the strongest predictors of fracture risk [10–12],
many regulatory agencies worldwide, including the Swiss
health authorities [13], have adopted these criteria for reim-
bursement and ipso facto as intervention thresholds. In
Switzerland, bisphosphonates, and more recently the mono-
clonal antibody denosumab, are generally reimbursed if the
patient has a BMD T-score≤−2.5 SD at the lumbar spine or the
hip. The available SERMs (raloxifene and bazedoxifene) are
reimbursed at a T-score value of −1 SD or below. In addition,
all bone active substances are generally reimbursed if the
patient has sustained a fragility fracture.
T-score-based intervention in osteoporosis has the merit of
simplicity for payers, controllers, physicians, and patients.
However, prospective epidemiological studies have shown that
many fractures occur in individuals with a BMD T-score value
above the operational threshold [14, 15]. In the Swiss Osteo-
Care survey, more than half of all patients presenting at an
emergency ward with a fragility fracture had BMD measured
byDXA at the lumbar spine or the hip above −2.5 SD, of which
two thirds had osteopenia [16]. Similarly, in a Swiss fracture
service liaison service, 60% of the patients with a fragility
fracture had BMD values above −2.5 SD [17].
Currently, there is no universally accepted policy for
screening to identify patients at high risk of fracture so that
individual patient identification depends on a case-finding
strategy generally relying upon the detection of individuals
with clinical risk factors for fracture in whom BMD tests are
subsequently undertaken [1]. Recently, the FRAX® assess-
ment algorithm (http://www.shef.ac.uk/FRAX), which is
based on an individual risk factor profile, has been calibrated
for Swiss-specific fracture risk and life expectancy [3, 18, 19].
It identified several constellations of risk factors in which
patients were at identical or higher level of fracture risk than
that based on the T-score alone [18]. In other words, individ-
uals at high fracture risk could be identified who, on the basis
of BMD testing, would be ineligible for treatment under
current guidance. Conversely, individuals at low fracture risk
could be identified who, on the basis of BMD testing, would
be eligible for treatment under current guidance. With the
development of probability-based fracture assessment, the
question arises at what threshold of fracture probability inter-
vention should be recommended.
Due to the large epidemiological and economical variabil-
ity across countries, cost-effective intervention thresholds
based on FRAX® will by nature be country-specific. As an
example, in the UK, a probability for a major osteoporotic
fracture of 7% was considered a cost-effective intervention
threshold [20] and in the US, a 3% probability for hip fracture
and 20% probability for any major osteoporotic fracture were
recommended as cost-effective [21–23].
The objective of the present analysis was to characterize
intervention thresholds in a Swiss setting, with branded alendr-
onate in women and men aged 50 years or more that could be
justified from a cost-effectiveness assessment.
Methods
Two FRAX®-based approaches were used to explore inter-
vention thresholds. The first was to determine the fracture
probability at which intervention became cost-effective. The
second approach was to examine the cost-effectiveness of
intervention thresholds developed in the UK by the National
Osteoporosis Guideline Group (NOGG) [24] applied to a
Swiss setting. NOGG recommends a case-finding approach
incorporating FRAX, with or without BMD. Intervention
thresholds are age-specific and based on the probability of
fracture in women presenting with history of a prior fragility
fracture, irrespective of BMD. The rationale for this derives
from the fact that many guidelines [24–27], including in
Switzerland [28], recommend that women with a prior fra-
gility fracture should be considered for treatment. Thus, indi-
viduals with a fracture probability equal to or exceeding that
of women with a prior fragility fracture should also be con-
sidered for treatment. This approach, derived from prior
guidelines in the UK [27], is in effect a translation of old
guidelines to probability-based fracture risk assessment—and
has been termed a “translational approach” [29].
Ten-year probabilities of major osteoporotic fractures were
calculated using the Swiss-specific FRAX® tool [3, 18]. The
distributions of clinical risk factors and BMD in women were
assumed to be identical to those in the original FRAX®
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cohorts [30, 31], which were cross-validated with the Swiss
Evaluation ofMeasurement methods of Osteoporosis Fracture
risk (SEMOF) cohort [32].
The cost-effectiveness of branded alendronate was com-
pared to no intervention in a Swiss setting by simulating costs
and outcomes in cohorts of women andmen aged 50 years and
older at different probabilities for a major osteoporotic fracture.
The perspective was that of the Swiss healthcare system. Only
direct medical costs were included. Health effects were mea-
sured as quality-adjusted life-years gained (QALYs, i.e., taking
into account quality of life as well as life-years) and major
results are presented as the incremental cost-effectiveness ratio
(ICER).
Utilities
As no utility data are available for Switzerland, we used age-
specific utility data from a representative sample of the
population of the United Kingdom assessed by the EuroQoL
EQ-5D questionnaire, encompassing the health dimensions
of mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression [33]. The effect of fractures on quality of
life during the first year post event was based on Swedish
estimates for disutility following hip, vertebral, forearm,
[34], and other fractures [35]. For subsequent years, the quality
of life after a hip, vertebral, and radius fracture were estimated
at 91%, 93%, and 100% of that of an age-matched healthy
individual, respectively [36].
Simulation model
The simulation model was an adaptation of a well-validated
transition state Markov cohort model suggested as a refer-
ence model for the evaluation of osteoporotic treatments
[37–39]. Details of the model structure have been previously
described [20, 36, 40–42].
Population fracture risks and mortality
Age-differentiated annual fracture risks in the Swiss popu-
lation for hip, vertebral, and forearm fractures were derived
from a previous study [2]. Country-specific population frac-
ture risks for other fracture sites (pelvis, rib, humerus, tibia,
fibula, clavicle, scapula, sternum, and other femoral frac-
tures) were not available. Fracture risks at these sites were
imputed from more complete Swedish data [43, 44] by
assuming that the age-specific ratio between the incidence
of hip fracture and other fractures in Switzerland would be
similar to that in Sweden.
Age-specific population mortality for men and women
was derived from WHO statistics for year 2008 [45]. A
FRAX®-dependent relative risk of death based on a
patient’s risk factor profile was applied to the mortality rates
to reflect the mortality in the simulated patients’ groups.
Age-differentiated relative risk of death (first and following
years) after hip and clinical vertebral fractures were derived
from earlier studies [46–48]. Excess mortality after fractures
at these sites is in part related to co-morbidity [48, 49], and it
was assumed that 30% of the excess mortality was causally
related to the fracture event itself [42, 50, 51]. Forearm frac-
tures were assumed not to entail increased mortality. Relative
risk of death during the first year after “other fracture” was
assumed to be 1.22 [52].
Effect of treatment
The effects of alendronate on fracture risk were taken from
the systematic review used for NICE guidance with the
following relative risks (95% confidence interval): hip frac-
ture 0.62 (0.40–0.96), vertebral fracture 0.56 (0.46–0.67),
distal forearm, and proximal humerus fracture 0.85 (0.67–
1.09) [53]. An intervention for 5 years was modelled as used
in other studies [36, 42, 54, 55]. Treatment period was
5 years assuming 50% dropouts during the first half-year
cycle and no dropouts thereafter [56, 57]. After stopping
treatment, risk reduction was assumed to reverse in a linear
manner over 5 years as generally assumed in health eco-
nomic analyses with bisphosphonates [36, 54, 56] and con-
sistent with results from clinical studies with alendronate
[58, 59]. Gastrointestinal side effects were assumed to lead
to 23.5 additional GP consultations per 1,000 patient-
months in the initial treatment period and 3.5 thereafter,
and to require the use of a proton pump inhibitor. Symptoms
were assumed to persist for 1 month with a utility loss
equivalent to a multiplier of 0.91 as used in the appraisals
of NICE [60].
Cost assumptions
A public price Swiss Francs (CHF) 504.00 per full treatment
year with branded alendronate was used for health economic
modelling. Proton-pump inhibitors were costed at CHF 4.25
per tablet for branded omeprazole and CHF 2.65/tablet for
generic omeprazole (public prices excluding VAT).
The cost of a physician visit was CHF 40.00 for 15 min
consultation with incremental CHF 51.00 for rapid clinical
examination or CHF 85.00 for an extensive clinical exami-
nation and CHF 7.40 if drugs were dispensed instead of
prescribed. The cost of a BMD measurement including
fracture risk assessment, an extensive clinical examination,
fracture risk assessment, treatment initiation, and instruc-
tions to patients was set at CHF 300.00, as used earlier
[56]. Year 2000 costs were adjusted for inflation according
to OECD statistics (index 100 in year 2000, 108.8 in year
2008) [61]. Thus, the cost of BMD was inflated to CHF
326.00 corresponding to CHF 75.00 for BMD measurement
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by DXA at a single site and CHF 251.00 for added medical
services, including medical risk assessment.
Daily inpatient cost in acute care and rehabilitation facili-
ties were CHF 1,009.00 and CHF 440.00 in year 2000,
respectively [2, 56]. They were adjusted for inflation as de-
scribed above. The length of acute hospital stay was assumed
to be 17.4 days for a hip fracture, 18.0 days for a clinical spine
fracture, and 6.4 days for a fracture of the distal radius [2]. The
participation rate in a rehabilitation program after hip fracture
was set at 68% of women and 36% ofmen for a mean duration
of stay in the rehabilitation program of 59 and 54 days,
respectively [62]. The cost of per day in a nursing home was
CHF 187.00/day [56], corresponding to CHF 203.00 after
adjustment for inflation.
The probability of being hospitalized after a clinical spine
fracture was 33% and 53% after a distal radius fracture [3,
63]. The ambulatory costs of fracture were set at CHF
6,442.00, CHF 2,250.00, and CHF 5,628.00 for hip, spine,
and distal forearm fractures, respectively [56, 64]. As used
earlier, a discount rate for costs and effects of 3% per year
was applied [56].
Determination of the intervention thresholds
There is no generally accepted or recommended cost-
effectiveness threshold for medical interventions in Switzer-
land. WHO has suggested a value of three times the gross
domestic product (GDP) per capita as the disability-adjusted
life-years (DALY) value to be used as cost-effectiveness thresh-
old in countries with developing economies [65], whereby a
DALY can be reasonably assumed comparable to a QALY
[66]. Borgström et al. [67] have suggested a willingness to
pay (WTP) of 2× GDP/capita for industrialized countries. In
this report, the threshold value for a quality-adjusted year of life
was defined as a willingness-to-pay corresponding to two times
Swiss GDP/capita in year 2008 (i.e., 2× CHF 70,272) pub-
lished by the Swiss Federal Statistical Office (SFSO) [68]. A
sensitivity analysis at lower WTP thresholds of 1 and 1.5×
GDP/capita was also performed.
Intervention thresholds at each age were determined
from the relationship between fracture probabilities and
the cost-effectiveness of all possible combinations of
CRFs at T-scores between 0 and −3.5 SD in 0.5 SD
steps (512 combinations) with a BMI set to 25 kg/m2
for each sex and each age (55, 60, 65, 70, 75, 80, and 85 years).
Thus, the point generated estimates reflect an unweighted
array of possible combinations and not a population
simulation.
For the cost-effectiveness approach, piecewise linear re-
gression with 10-year probability (%) for osteoporotic frac-
ture (calculated with BMD) as the independent and ICER as
dependent variables was applied. A standard-deviation
around the regression line was calculated and used to
determine 95% tolerance intervals. The term tolerance in-
terval is used since the regression points are not drawn from
a population sample but an array of different clinical scenar-
ios. For the translational approach, the FRAX probability of
a major osteoporotic fracture for a Swiss woman with a
previous fragility fracture was calculated for each age, with
BMI set at 25 kg/m2, no other clinical risk factors, and no
BMD. Thereafter, for both sexes at each age and at the
specific FRAX values, the corresponding tolerance interval
of the ICER was derived from its standard deviation around
the regression line.
Results
Cost-effectiveness approach
There was a close relationship between the 10-year probability
of a major osteoporotic fracture, derived from the combina-
tions of clinical risk factors and BMD, and the ICER at all
ages. Results for women andmen at the age of 65 and 80 years
are shown in Fig. 1. At the chosenwillingness to pay threshold
(CHF 140,000/QALY), which corresponds to twice GDP per
capita, a majority of the risk factor combinations were cost-
effective in women and men at either age. An ICER with a
null value may even represent a cost-saving situation.
As shown in Table 1, the intervention threshold (i.e., the
fracture probability at which treatment became cost-effective)
was relatively stable across all ages and similar in both sexes.
The arithmetic mean probability of a major osteoporotic frac-
ture across all age groups at which it became cost-effective to
intervene with alendronate was 13.8% (95% tolerance interval
12.3 to 15.9%) and 15.1% (95%TI 12.6 to 20.7%) in women
and men, respectively. Therefore, on average, an inter-
vention aimed at reducing fracture risk with alendronate
can be considered as generally cost-effective in Switzerland
when the 10-year probability of a major osteoporotic fracture
exceeds 14% inwomen and 15% inmen aged 50 years or more.
Translational approach
The cost-effectiveness of treating women andmen for prevent-
ing fractures at a FRAX® probability threshold corresponding
to a major osteoporotic fracture probability equivalent to that
of women with a positive history of fragility fracture with
branded alendronate is shown in Table 2. For this universally
accepted risk factor and hence probability level for a major
osteoporotic fracture, intervention against fracture was cost-
effective from the age of 60 years in women and 55 years
in men.
As shown in Fig. 2, the intervention thresholds obtained
by following a cost-effectiveness approach are consistently
lower than those resulting from the translational approach in
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both women and men. This shows that interventions aimed at
reducing fracture risk in osteoporotic patients can be imple-
mented in a cost-effective manner in patients at high risk of
fracture characterized by a FRAX threshold lower than that of
patients with prevalent fractures.
As shown in Figure 3, the strategic choice of a cost-
effective vs. a translational threshold also has consequences
with regard to the distribution of the population eligible for
intervention, as an age-independent threshold (cost-effec-
tiveness approach) results in mainly elderly being eligible
for treatment while an age-dependent threshold based on
fracture risk equivalence (translational approach) skews the
distribution towards younger persons. However, as the
FRAX®-based intervention threshold should be considered
incremental to already accepted intervention thresholds (i.e.,
in addition to patients with a positive history of fracture and/
or a T-score ≤−2.5 SD), the increase in the target population
at high probability of fracture being given access to treat-
ment based on FRAX® will be relatively small. Overall,
assuming an intervention threshold equivalent to or higher
than the 10-year fracture probability of a person with a
prevalent fragility fracture during adulthood (age-dependent
intervention threshold, translational approach), 25.8% of all
Swiss women (3.4% of men) aged 50 years or older would
be eligible for a targeted intervention based on equivalent
fracture risk. Alternatively, assuming an intervention thresh-
old defined as a 10-year probability for any major osteopo-
rotic fracture of 15% or more at any age (age-independent
intervention threshold, cost-effectiveness approach), 43.8%
of all women (6.9% of men) aged 50 years and older living
in Switzerland would be eligible for a cost-effective
FRAX®-based intervention aimed at reducing fracture risk.
These patient populations will expectedly overlap in part
with patient populations currently eligible for treatment,
i.e., patients with a positive history of fracture and/or a
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Fig. 1 Association between the 10-year probability of a major
osteoporotic fracture and cost-effectiveness. BMI was set to
25 kg/m2. The cost-effectiveness threshold was set at a willingness
to pay of 2× GDP/capita
Table 1 Ten-year probabilities (percent) of a major osteoporotic fracture
(with 95% tolerance interval; TI) at which it was cost-effective to intervene
with alendronate with a cost-effectiveness threshold set at a willingness to
pay of 2× GDP/capita
Age (years) Women Men
Probability 95% TI Probability 95% TI
55 14.1 12.1–17.3 9.9 9.2–12.8
60 14.4 11.6–17.2 12.0 9.9–14.9
65 12.8 11.9–17.5 13.9 11.7–16.2
70 14.4 13.3–15.5 17.5 14.9–20.9
75 14.8 13.2–16.3 19.9 15.6–31.2
80 15.0 14.4–15.6 19.0 16.0–28.7
85 10.8 9.6–12.0 13.5 11.0–19.9
Arithmetic
mean
13.8 12.3–15.9 15.1 12.6–20.7
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T-score ≤−2.5 SD and give access to targeted fracture risk
reduction interventions to those at increased clinical fracture
risk based on their FRAX®-score.
Sensitivity analysis
The cost-effective intervention thresholds derived from the
cost-effectiveness approach in relation to WTP cut-offs of
2.0, 1.5×, and 1.0× GDP per capita are shown in Fig. 4. As
expected, the mean cost-effective intervention threshold
increases with decreasing WTP, from 13.8 to 16.3 and 20.1%
in women and from 15.1 to 16.9 and 19.9% in men, respec-
tively. Interestingly, age-dependent variations around these
mean values were modest: 14.1%, 12.8%, 14.8%, 10.8% and
9.9%, 13.9%, 19.9%, 13.5% in 55-, 65-, 75-, and 85-year-old
women and men in the base case scenario, respectively.
Discussion
The currently accepted criteria for treatment of osteoporosis
in Switzerland are a BMD T-score≤−2.5 SD or a prevalent
fragility fracture. The present study shows that intervention
can be delivered cost-effectively in women and men in
whom the 10-year probability for a major osteoporotic frac-
ture is approximately 15% or more. Age-dependent varia-
tions around these mean values were modest. We
additionally show that treatment is cost-effective in patients
with a fracture probability equivalent to that of a woman
with a prior fragility fracture and no other clinical risk
factors in women and men from the age of 60 and 55 years,
respectively. These findings indicate that treatment should
be considered in women and men who exceed these proba-
bility thresholds, irrespective of the presence of a prior
fracture or a specific T-score criterion.
Several surveys indicate that half or more of all patients
presenting with a fragility fracture have BMD T-scores at the
lumbar spine or the hip higher than −2.5 SD, i.e., are not
osteoporotic [69–71] and similar findings are reported in
studies based in Switzerland [16, 17]. In Switzerland, drug
therapy against osteoporosis with a bisphosphonate or deno-
sumab is generally reimbursed if the patient has a T-score at or
below −2.5 SD and/or a prevalent fragility fracture. Thus, the
reimbursement policy disenfranchises a segment of the popu-
lation at risk. For example, a woman aged 65 years with a
prior fragility fracture and no other clinical risk factors has a
10-year probability of a major fracture of 18% (FRAX v3.4
available at http://www.shef.ac.uk/FRAX) and qualifies for
reimbursed treatment under current restrictions. In contrast, a
woman of the same age, with a parental history of hip fracture,
and on an average dose of glucocorticoids, is currently ineli-
gible even though her fracture probability is higher than the
woman with the fragility fracture (27% vs. 18%). Although
treatment is cost-effective of both patients, it is more cost-
effective in the latter case.
Table 2 Incremental cost-effectiveness ratio (with 95% confidence interval; CI) of intervention at a 10-year probability of major osteoporotic
fracture equivalent to that in persons with a positive history of fragility fracture
Age (years) Risk of major osteoporotic fracture
with a positive history of fragility fracture
ICER (95% CI)
Women Men
55 13.0% 168,683 (117,246–220,119) 101,304 (65,053–137,556)
60 16.0% 119,113 (83,211–155,014) 96,431 (65,143–127,718)
65 18.0% 95,035 (53,725–136,345) 80,023 (38,783–121,263)
70 25.0% 44,492 (20,268–68,715) 0 (0–120,839)
75 37.0% 2,779 (0–20,538) 0 (0–116,155)
80 41.0% 0 (0–10,939) 0 (0–120,746)
85 41.0% 0 (0–12,541) 29 (0–138,182)
Scenarios where the ICER was less than a WTP of CHF 140,000/QALY (twice GDP per capita) gained are highlighted in bold
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Fig. 2 Intervention thresholds for drug therapy reducing fracture risk at
the female and male population level: translational approach (age-depen-
dent risk equivalence with positive history of fragility fracture) vs. cost-
effectiveness approach (cost-effective intervention threshold by sex)
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In order to overcome this inequity, the Swiss 2010 edition
of recommendations for the diagnosis and treatment of oste-
oporosis issued by the Swiss Association against Osteoporosis
(SVGO/ASCO) also recommend drug therapy aimed at re-
ducing fracture risk for such patients [28]. A FRAX®-based
age-dependent intervention cut-off was recommended based
on a translational approach, i.e., where the fracture probability
exceeded that of a woman with a prior fragility fracture.
Whereas this recommendation is cost-effective, as shown in
the present study, it does not fully exploit the potential for
cost-effective interventions derived from ICER-dependent
thresholds. Using this approach, patients with a FRAX® prob-
ability for any major osteoporotic fracture of 15% or more
could be treated cost-effectively.
Approximately 44% of women aged 50 years or more in
Switzerland have a 10-year fracture probability that exceeds
15%. The proportion of women with a fracture probability
exceeding that of a woman with a prior fracture is 26%. In
practice, the increment in the number of women eligible for
treatment will be substantially less than 18% (44% minus
26%) because many will already have qualified for treat-
ment on the basis of BMD or prior fracture criteria. In any
case, using FRAX-based intervention thresholds instead of
or in addition to currently accepted criteria will lead to an
increase in health care resource allocation which could be
compensated by shifting budgets from less or not cost-
effective healthcare interventions towards documented cost-
effective interventions such as the treatment of osteoporosis
with alendronate based on the FRAX thresholds proposed in
the present analysis.
Branded alendronate (alendronate OM) was chosen for
the present analysis as it was the most frequently prescribed
oral bisphosphonate in Switzerland in year 2008. We as-
sumed treatment with alendronate OM at an annual cost of
CHF 504.00. In 2011, the annual cost is CHF 485.10, so that
our results are marginally conservative at today’s prices.
However, other treatments for osteoporosis are available,
such as generic alendronate (mean annual drug price of
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Fig. 4 Sensitivity analysis. Cost-effective intervention thresholds
at WTP of 2.0×, 1.5×, and 1.0× GDP per capita in women and
men
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intervention thresholds
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CHF 361.00, −26% vs. alendronate OM), zoledronate for
yearly IV infusion (mean annual drug price of CHF 686.65,
excluding cost of administration, +29% vs. alendronate OM)
and denosumab for subcutaneous injection (mean annual drug
price of CHF 717.00, excluding cost of administration, +32%
vs. alendronate OM). Thus, the cost-effectiveness of each
therapeutic intervention varies, even when assuming equal
efficacy. It could be argued from an economic perspective that
each agent would have a different intervention threshold de-
termined by its individual cost-effectiveness. Therefore, there
are some patients who cannot take alendronate and who are at
a too-low risk to start an alternative treatment purely based on
cost-effectiveness. As argued elsewhere [72], this sets an
ethical dilemma for the primary care physician in that patients
who cannot take alendronate would not be afforded any
treatment until their condition had deteriorated sufficiently to
provide an alternative treatment. In order to avoid the prob-
lem, the National Osteoporosis Guideline Group in the UK
used the same intervention thresholds for these alternative
agents as used for (generic) alendronate despite their higher
price [24]. This position was taken because cost-effective
scenarios for these interventions were found at a WTP of
GBP 20,000–30,000/QALY which is currently accepted by
NICE in the UK [72].
Lower price is an argument for extending treatment to
patients at lower risk which may give head room for innova-
tion; i.e., free resources for new treatments (within or outside
osteoporosis). Assuming, for example, that all treatments have
equal efficacy if used in the correct population, and that the
cost of an alternative to generic alendronate was CHF 700.00
per year, then 42% of patients could be offered such new
treatments without prejudicing the average cost-effectiveness
of an intervention program [20].
Whereas direct comparative head-to-head fracture endpoint
trials between alendronate and alternatives are lacking, evi-
dence to date suggests that, at least in terms of fracture risk
reduction, zoledronic acid and denosumab aremore efficacious
than alendronate OM [53]. On the other hand, clinical equiv-
alence between generic and branded bisphosphonates has been
recently challenged [73–75]. Clinical chart reviews [74] and
the experience of switching from branded to generic formula-
tions [75] suggest that a number of generic formulations are
associated with poorer adherence, more frequent side effects,
and thus poorer effectiveness than branded agents. This obser-
vation of poorer persistence with generic bisphosphonates has
implications for cost-effectiveness and is likely to favor the
incremental cost-effectiveness of alternative agents [52]. In the
present analysis, the adherence assumptions with branded
alendronate were consistent with those used in previous work
[56, 57]. While the importance of adherence on clinical and
economical outcomes is increasingly recognized [76],
using other assumptions would have increased or de-
creased the cost-effective intervention threshold but not
altered the principal conclusion of the present analysis, which
is that this threshold is not age-dependent.
The interpretation of our results is dependent on the WTP
assumed. There are no universally accepted cost-effectiveness
thresholds, but the WHO Commission on Macroeconomics
and Health [65] suggests that interventions with a cost-
effectiveness ratio lower than three times the GDP per capita
for each averted disability-adjusted life year (DALY) should be
considered to be cost-effective. Assuming that the values for a
DALY and a QALY are reasonably comparable [66], a cost-
effective threshold for Switzerland would be CHF 211,000. It
is not specified in the report of the WHO Commission what
costs are included, but if all costs are included, such as cost of
added life-years, then the threshold value should be set at a
lower level when a health-care perspective is taken. For this
reason, we used a WTP threshold of twice GDP in accordance
with previous recommendations [66, 77].We also explored the
effects of more conservative scenarios. With a WTP equal to
GDP, cost-effective scenarios were found at a 10-year fracture
probability of 20% rather than 15% as used in the base case.
Patients included in fracture endpoint trials with alendro-
nate were not recruited based on FRAX® or clinical risk
factors but on T-score values and/or prevalence of vertebral
fractures. The present health economic evaluation assumes
that similar fracture risk reduction effects will be obtained if
alendronate was used in patients recruited on the basis of their
FRAX® score. In the meantime, the adequacy of this assump-
tion has been validated for one bisphosphonate (clodronate
[78]), two selective estrogen receptor modulators (basedoxi-
fene [79] and raloxifene [80]), and denosumab [81]. In these
analyses, high FRAX® probabilities were associated with
treatment efficacy even when BMD was not used, supporting
the use of this assumption for other bone active substances
proven to reduce fracture risk such as alendronate. In addition,
selection of high-risk patients on the basis of FRAX (without
BMD) preferentially selects patients with low BMD [82].
A limitation of our study is that the sensitivity analysis was
restricted to three WTP thresholds. However, while a detailed
univariate sensitivity analysis would have increased or de-
creased the proposed intervention thresholds, it would not
have altered the conclusion, which is that age has little to no
influence on these thresholds. The epidemiological and cost
data used in the present model relied mainly on previously
published data from year 2000 [83] which is a limitation of our
study. However, cost input parameters were adjusted for in-
flation up to year 2008. Furthermore, while hospitalizations
for hip fractures have declined and the average length of
hospital stay after fracture has decreased in Switzerland be-
tween 2000 and 2008, the total cost of hospitalizations for
major osteoporotic fractures have increased by 27.7% in
women and 36.4% in men as a combined effect of a rapidly
ageing population, increasing daily costs of hospitalizations,
and increasing absolute number of hospitalizations for such
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fractures [83, 84]. Therefore, we believe that the epidemio-
logical and cost assumptions underlying modelling results
remain conservative. Finally, it should be kept in mind that
intervention thresholds based on health economic modelling
results should not be used alone for clinical decision making.
The thresholds identified in the present analysis should be
used in conjunction with all clinically relevant patient charac-
teristics beyond the individual FRAX score.
Conclusion
In Switzerland, drug intervention aimed at decreasing fracture
risk is cost-effective in all women and men aged 50 years and
older with a 10-year probability for a major osteoporotic
fracture calculated with the Swiss specific FRAX® algorithm
at or above 15%. Using this intervention threshold, the
FRAX® score should contribute to open access to therapy to
patients at high fracture probability based on clinical risk
factors and to thereby further reduce the growing burden of
osteoporotic fractures in Switzerland.
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